Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 2/2006

01-02-2006 | Letter to the Editors

Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter

Authors: Francois Cachat, Daniel Bardy, Claudine Durussel, Ermindo Di Paolo

Published in: Pediatric Nephrology | Issue 2/2006

Login to get access

Abstract

Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.
Literature
1.
Dunea G, Domenico L, Gunnerson P, Winston-Willis F (1991) A survey of permanent double lumen catheters in hemodialysis patients. ASAIO Trans 37:M276–277PubMed
2.
Daeihagh P, Jordan P, Chen J, Rocco M (2000) Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36:75–79PubMed
3.
Gittins M, Coulthard MG, Matthews JNS (2005) Alteplase v Heparin locks to maintain central line patency in hemodialysis lines. Arch Dis Child 90 [Suppl 11]:A30
4.
Schenk P, Rosenkranz AR, Wolfl G, Horl WH, Traindl O (2000) Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. Am J Kidney Dis 35:130–136PubMed
5.
McBryde KD, Wilcox J, Kher KK (2005) Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 20:1182–1185CrossRefPubMed
6.
Rowe RC, Sheskey PJ, Weller PJ (2003) Handbook of pharmaceutical excipients, 4th edn. Pharmaceutical Press, London, pp 442–443
7.
Ball CL, Tobler K, Ross BC, Connors MR, Lyon ME (2004) Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med 42:107–108CrossRefPubMed
8.
Cohen AM, Magazanik A, van-der Lijn E, Shaked P, Levinsky H (1994) Pseudohyperphosphatemia incidence in an automatic analyzer. Eur J Clin Chem Clin Biochem 32:559–561PubMed
9.
Mandry JM, Posner MR, Tucci JR, Eil C (1991) Hyperphosphatemia in multiple myeloma due to a phosphate binding immunoglobulin. Cancer 68:1092–1094PubMed
10.
Lelhey DJ, Daugirdas JT, Ing TS, Reid RW (1985) Spurious hyperphosphatemia due to hyperlipidemia. Arch Int Med 145:743–744CrossRef
Metadata
Title
Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter
Authors
Francois Cachat
Daniel Bardy
Claudine Durussel
Ermindo Di Paolo
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 2/2006
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-005-2088-1

Other articles of this Issue 2/2006

Pediatric Nephrology 2/2006 Go to the issue

Original Article

Renal transplant biopsy specimen adequacy in a paediatric population

Original Article

Intracellular cytokines in peripheral blood leucocytes in children with chronic renal failure

Brief Report

Hypokalemia causing rhabdomyolysis resulting in life-threatening hyperkalemia

Educational Feature

A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H

Original Article

Long-term outcome of chronic dialysis in children

Original Article

Hypophosphatemic rickets: results of a long-term follow-up